The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factorα

Naoyasu Ueda, Hiroshi Tsukamoto, Hiroki Mitoma, Masahiro Ayano, Atsushi Tanaka, Shun Ichiro Ohta, Yasushi Inoue, Yojiro Arinobu, Hiroaki Niiro, Koichi Akashi, Takahiko Horiuchi

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Anti-tumor necrosis factor α (anti-TNF-α) agents have been successfully applied for the treatment of rheumatoid arthritis, Crohn's disease, and other chronic inflammatory diseases. Not only the neutralization of soluble TNF-α but also the effect on transmembrane TNF-α is important mechanisms of action of anti-TNF-α agents. This study investigated the cytotoxic effects of new anti-TNF-α agents, certolizumab pegol and golimumab, which are mediated by transmembrane TNF-α. Methods: Transmembrane TNF-α-expressing Jurkat T cells that did not express TNF receptors were used. The binding ability of each anti-TNF-α agent to transmembrane TNF-α, antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and the apoptotic effect were examined. Results: Certolizumab pegol and golimumab bound to transmembrane TNF-α. Golimumab induced antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, which was comparable to infliximab and adalimumab. However, certolizumab pegol did not induce antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity. Certolizumab pegol directly induced nonapoptotic cell death in transmembrane TNF-α-expressing cells. Golimumab induced a weaker apoptotic effect than infliximab and adalimumab. Conclusions: The cytotoxic effects of anti-TNF-α agents on TNF-α-expressing cells are considered to be associated with the clinical effect of these agents on granulomatous diseases. The direct cytotoxic effect of certolizumab pegol on TNF-α-producing cells may contribute to its clinical efficacy in Crohn's disease. Golimumab may be less effective for granulomatous diseases.

Original languageEnglish
Pages (from-to)1224-1231
Number of pages8
JournalInflammatory Bowel Diseases
Volume19
Issue number6
DOIs
Publication statusPublished - May 1 2013

Fingerprint

Antibody-Dependent Cell Cytotoxicity
Tumor Necrosis Factor-alpha
Crohn Disease
Jurkat Cells
Tumor Necrosis Factor Receptors
Rheumatoid Arthritis
Chronic Disease
Cell Death
golimumab
Certolizumab Pegol
T-Lymphocytes
Adalimumab
Infliximab

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Gastroenterology

Cite this

The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factorα. / Ueda, Naoyasu; Tsukamoto, Hiroshi; Mitoma, Hiroki; Ayano, Masahiro; Tanaka, Atsushi; Ohta, Shun Ichiro; Inoue, Yasushi; Arinobu, Yojiro; Niiro, Hiroaki; Akashi, Koichi; Horiuchi, Takahiko.

In: Inflammatory Bowel Diseases, Vol. 19, No. 6, 01.05.2013, p. 1224-1231.

Research output: Contribution to journalArticle

@article{0aeebd5865a645bf979ba2144bb79266,
title = "The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factorα",
abstract = "Background: Anti-tumor necrosis factor α (anti-TNF-α) agents have been successfully applied for the treatment of rheumatoid arthritis, Crohn's disease, and other chronic inflammatory diseases. Not only the neutralization of soluble TNF-α but also the effect on transmembrane TNF-α is important mechanisms of action of anti-TNF-α agents. This study investigated the cytotoxic effects of new anti-TNF-α agents, certolizumab pegol and golimumab, which are mediated by transmembrane TNF-α. Methods: Transmembrane TNF-α-expressing Jurkat T cells that did not express TNF receptors were used. The binding ability of each anti-TNF-α agent to transmembrane TNF-α, antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and the apoptotic effect were examined. Results: Certolizumab pegol and golimumab bound to transmembrane TNF-α. Golimumab induced antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, which was comparable to infliximab and adalimumab. However, certolizumab pegol did not induce antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity. Certolizumab pegol directly induced nonapoptotic cell death in transmembrane TNF-α-expressing cells. Golimumab induced a weaker apoptotic effect than infliximab and adalimumab. Conclusions: The cytotoxic effects of anti-TNF-α agents on TNF-α-expressing cells are considered to be associated with the clinical effect of these agents on granulomatous diseases. The direct cytotoxic effect of certolizumab pegol on TNF-α-producing cells may contribute to its clinical efficacy in Crohn's disease. Golimumab may be less effective for granulomatous diseases.",
author = "Naoyasu Ueda and Hiroshi Tsukamoto and Hiroki Mitoma and Masahiro Ayano and Atsushi Tanaka and Ohta, {Shun Ichiro} and Yasushi Inoue and Yojiro Arinobu and Hiroaki Niiro and Koichi Akashi and Takahiko Horiuchi",
year = "2013",
month = "5",
day = "1",
doi = "10.1097/MIB.0b013e318280b169",
language = "English",
volume = "19",
pages = "1224--1231",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factorα

AU - Ueda, Naoyasu

AU - Tsukamoto, Hiroshi

AU - Mitoma, Hiroki

AU - Ayano, Masahiro

AU - Tanaka, Atsushi

AU - Ohta, Shun Ichiro

AU - Inoue, Yasushi

AU - Arinobu, Yojiro

AU - Niiro, Hiroaki

AU - Akashi, Koichi

AU - Horiuchi, Takahiko

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Background: Anti-tumor necrosis factor α (anti-TNF-α) agents have been successfully applied for the treatment of rheumatoid arthritis, Crohn's disease, and other chronic inflammatory diseases. Not only the neutralization of soluble TNF-α but also the effect on transmembrane TNF-α is important mechanisms of action of anti-TNF-α agents. This study investigated the cytotoxic effects of new anti-TNF-α agents, certolizumab pegol and golimumab, which are mediated by transmembrane TNF-α. Methods: Transmembrane TNF-α-expressing Jurkat T cells that did not express TNF receptors were used. The binding ability of each anti-TNF-α agent to transmembrane TNF-α, antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and the apoptotic effect were examined. Results: Certolizumab pegol and golimumab bound to transmembrane TNF-α. Golimumab induced antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, which was comparable to infliximab and adalimumab. However, certolizumab pegol did not induce antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity. Certolizumab pegol directly induced nonapoptotic cell death in transmembrane TNF-α-expressing cells. Golimumab induced a weaker apoptotic effect than infliximab and adalimumab. Conclusions: The cytotoxic effects of anti-TNF-α agents on TNF-α-expressing cells are considered to be associated with the clinical effect of these agents on granulomatous diseases. The direct cytotoxic effect of certolizumab pegol on TNF-α-producing cells may contribute to its clinical efficacy in Crohn's disease. Golimumab may be less effective for granulomatous diseases.

AB - Background: Anti-tumor necrosis factor α (anti-TNF-α) agents have been successfully applied for the treatment of rheumatoid arthritis, Crohn's disease, and other chronic inflammatory diseases. Not only the neutralization of soluble TNF-α but also the effect on transmembrane TNF-α is important mechanisms of action of anti-TNF-α agents. This study investigated the cytotoxic effects of new anti-TNF-α agents, certolizumab pegol and golimumab, which are mediated by transmembrane TNF-α. Methods: Transmembrane TNF-α-expressing Jurkat T cells that did not express TNF receptors were used. The binding ability of each anti-TNF-α agent to transmembrane TNF-α, antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and the apoptotic effect were examined. Results: Certolizumab pegol and golimumab bound to transmembrane TNF-α. Golimumab induced antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, which was comparable to infliximab and adalimumab. However, certolizumab pegol did not induce antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity. Certolizumab pegol directly induced nonapoptotic cell death in transmembrane TNF-α-expressing cells. Golimumab induced a weaker apoptotic effect than infliximab and adalimumab. Conclusions: The cytotoxic effects of anti-TNF-α agents on TNF-α-expressing cells are considered to be associated with the clinical effect of these agents on granulomatous diseases. The direct cytotoxic effect of certolizumab pegol on TNF-α-producing cells may contribute to its clinical efficacy in Crohn's disease. Golimumab may be less effective for granulomatous diseases.

UR - http://www.scopus.com/inward/record.url?scp=84879206045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879206045&partnerID=8YFLogxK

U2 - 10.1097/MIB.0b013e318280b169

DO - 10.1097/MIB.0b013e318280b169

M3 - Article

VL - 19

SP - 1224

EP - 1231

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 6

ER -